Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on May 28, 2014 1:32am

140 Views

Post# 22604015

Conference call

After listening to the conference call I have to say that it was a mild disappointment. Yes 11 of 19 with a strong immune response is very good. Also it's early in treatment with a lot to learn. The one response that Linda had that disappointed me was greatest tumor shrinkage was 28% which really is not great. After thinking it over would reduce my baseball rating to a double from a triple. Double is good but with AF continuing to bash I don't expect much stock movement without more news.

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”